Palbociclib and Letrozole in Advanced Breast Cancer
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A phase 2 study showed that progression-free survival was longer with palbociclib plus letrozole than with letrozole alone in the initial treatment of postmenopausal women with estrogen-receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We performed a phase 3 study that was designed to confirm and expand the efficacy and safety data for palbociclib plus letrozole for this indication. METHODS: In this double-blind study, we randomly assigned, in a 2:1 ratio, 666 postmenopausal women with ER-positive, HER2-negative breast cancer, who had not had prior treatment for advanced disease, to receive palbociclib plus letrozole or placebo plus letrozole. The primary end point was progression-free survival, as assessed by the investigators; secondary end points were overall survival, objective response, clinical benefit response, patient-reported outcomes, pharmacokinetic effects, and safety. RESULTS: The median progression-free survival was 24.8 months (95% confidence interval [CI], 22.1 to not estimable) in the palbociclib-letrozole group, as compared with 14.5 months (95% CI, 12.9 to 17.1) in the placebo-letrozole group (hazard ratio for disease progression or death, 0.58; 95% CI, 0.46 to 0.72; P<0.001). The most common grade 3 or 4 adverse events were neutropenia (occurring in 66.4% of the patients in the palbociclib-letrozole group vs. 1.4% in the placebo-letrozole group), leukopenia (24.8% vs. 0%), anemia (5.4% vs. 1.8%), and fatigue (1.8% vs. 0.5%). Febrile neutropenia was reported in 1.8% of patients in the palbociclib-letrozole group and in none of the patients in the placebo-letrozole group. Permanent discontinuation of any study treatment as a result of adverse events occurred in 43 patients (9.7%) in the palbociclib-letrozole group and in 13 patients (5.9%) in the placebo-letrozole group. CONCLUSIONS: Among patients with previously untreated ER-positive, HER2-negative advanced breast cancer, palbociclib combined with letrozole resulted in significantly longer progression-free survival than that with letrozole alone, although the rates of myelotoxic effects were higher with palbociclib-letrozole. (Funded by Pfizer; PALOMA-2 ClinicalTrials.gov number, NCT01740427 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [43]
In the citing paper
“Although palbociclib was the first CDK4/6 inhibitor to demonstrate clinical efficacy (Finn et al., 2016), there are two others that soon followed.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2016
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Self-citationCristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationFinn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Self-citationFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Beaver, J. A., Amiri-Kordestani, L., Charlab, R., Chen, W., Palmby, T., Tilley, A., Zirkelbach, J. F., Yu, J., Liu, Q., Zhao, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1185 · Cited by 373
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Finn, R. S., Aleshin, A., & Slamon, D. J. (2016) · Breast Cancer Research · doi:10.1186/s13058-015-0661-5 · Cited by 368
Self-citationMartín, M., Loibl, S., von Minckwitz, G., Morales, S., Martinez, N., Guerrero, A., Anton, A., Aktas, B., Schoenegg, W., Muñoz, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.2388 · Cited by 131
Dickler, M. N., Barry, W. T., Cirrincione, C., Ellis, M. J., Moynahan, M. E., Innocenti, F., Hurria, A., Rugo, H. S., Lake, D. E., Hahn, O. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1595 · Cited by 128
Self-citation
Cited by
Items 101–200 of 1,002
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
Slamon, D. J., Diéras, V., Rugo, H. S., Harbeck, N., Im, S.-A., Gelmon, K. A., Lipatov, O. N., Walshe, J. M., Martin, M., Chavez-MacGregor, M., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00137 · Cited by 200
Self-citationCombined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2210 · Cited by 196
Kornblum, N., Zhao, F., Manola, J., Klein, P., Ramaswamy, B., Brufsky, A., Stella, P. J., Burnette, B., Telli, M., Makower, D. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9331 · Cited by 189
“of randomly assigned patients 66 65 Age, years, median (range) 64 (39-92) 59 (35-85) Ethnicity White 56 (85) 49 (75) Black 8 (12) 11 (17) Other 2 (3) 5 (8) ECOG performance status 0 40 (61) 38 (58) 1 26 (39) 27 (42) Measurable disease 44 (67) 42 (65) Metastatic disease site Bone 44 (67) 46 (71) Lung 28 (42) 23 (35) Li…”
BackgroundBoyd, A. L., Aslostovar, L., Reid, J., Ye, W., Tanasijevic, B., Porras, D. P., Shapovalova, Z., Almakadi, M., Foley, R., Leber, B., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.007 · Cited by 187
“While absolute time scales cannot be translated directly from xenografts to human timelines, 2-fold prolongation of progression-free survival is considered highly promising in human oncology trials (Finn et al., 2016).”
Herzog, S. K., & Fuqua, S. A. W. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01564-x · Cited by 178
McCartney, A., Migliaccio, I., Bonechi, M., Biagioni, C., Romagnoli, D., De Luca, F., Galardi, F., Risi, E., De Santo, I., Benelli, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00666 · Cited by 180
“These consistent positive PFS results have been demonstrated in large phase III trials in the upfront setting [PALOMA-2 (6) for palbociclib plus letrozole; MONALEESA-2 (7) for ribociclib plus letrozole and MONARCH-3 (8) for abemaciclib plus letrozole or anastrozole], as well as in populations previously treated with E…”
BackgroundExpanding control of the tumor cell cycle with a CDK2/4/6 inhibitor
Freeman-Cook, K., Hoffman, R. L., Miller, N., Almaden, J., Chionis, J., Zhang, Q., Eisele, K., Liu, C., Zhang, C., Huser, N., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.009 · Cited by 189
Ding, M. Q., Chen, L., Cooper, G. F., Young, J. D., & Lu, X. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0378 · Cited by 188
Bidard, F.-C., Jacot, W., Kiavue, N., Dureau, S., Kadi, A., Brain, E., Bachelot, T., Bourgeois, H., Gonçalves, A., Ladoire, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5660 · Cited by 181
Giuliano, M., Schettini, F., Rognoni, C., Milani, M., Jerusalem, G., Bachelot, T., De Laurentiis, M., Thomas, G., De Placido, P., Arpino, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30420-6 · Cited by 186
Rugo, H. S., Huober, J., García-Sáenz, J. A., Masuda, N., Sohn, J. H., Andre, V. A. M., Barriga, S., Cox, J., & Goetz, M. (2021) · The Oncologist · doi:10.1002/onco.13531 · Cited by 183
“Lower rates of grade ≥3 neutropenia were seen with abemaciclib compared with other CDK4 and CDK6 inhibitors, which ranged from 59% to 66% in phase III trials of other CDK4 and CDK6 inhibitors [12, 13, 17].”
Self-citationNebenfuehr, S., Kollmann, K., & Sexl, V. (2020) · International Journal of Cancer · doi:10.1002/ijc.33054 · Cited by 187
Spring, L. M., Zangardi, M. L., Moy, B., & Bardia, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0142 · Cited by 178
“Cyclin-dependent kinase 6 is particularly important in promoting the proliferation of hematological precursors, and its inhibition is an on-target effect that results in the cytopenias seen with CDK4/6 inhibition [52, 53].”
BackgroundFundytus, A., Sengar, M., Lombe, D., Hopman, W., Jalink, M., Gyawali, B., Trapani, D., Roitberg, F., De Vries, E. G. E., Moja, L., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00463-0 · Cited by 178
Huppert, L. A., Gumusay, O., Idossa, D., & Rugo, H. S. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 164
“4%) in the palbociclib arm compared with the letrozole‐only arm.(128)”
Self-citationBrufsky, A. M., & Dickler, M. N. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0423 · Cited by 165
“The most common adverse events (AEs) with the combination were neutropenia, leukopenia, fatigue, nausea, arthralgia, and alopecia [9].”
BackgroundThill, M., & Schmidt, M. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918793326 · Cited by 172
Finn, R. S., Boer, K., Bondarenko, I., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y. V., Thummala, A., Voitko, N., Bananis, E., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05755-7 · Cited by 171
Self-citationCottu, P., D'Hondt, V., Dureau, S., Lerebours, F., Desmoulins, I., Heudel, P.-E., Duhoux, F. P., Levy, C., Mouret-Reynier, M.-A., Dalenc, F., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy448 · Cited by 173
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
Spring, L. M., Wander, S. A., Zangardi, M., & Bardia, A. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0769-3 · Cited by 170
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
Wang, X., Zhao, S., Xin, Q., Zhang, Y., Wang, K., & Li, M. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00747-x · Cited by 163
“All of them exhibited signi fi cant improvements in PFS and objective response rate (ORR) for postmenopausal women with HR + /HER2-advanced breast cancer, compared to AI monotherapy [2, 18 – 20].”
BackgroundMethodResultInfluentialDrug repurposing for breast cancer therapy: Old weapon for new battle
Aggarwal, S., Verma, S. S., Aggarwal, S., & Gupta, S. C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.012 · Cited by 163
“The open label PALOMA (Palbociclib: Ongoing Trials in the Management of Breast Cancer) clinical trials were designed recently with either aromatase inhibitor (letrozole) (PALOMA-1 or PALOMA-2 Trials) [111, 112] or Fulvestrant hormone therapies (PALOMA-3 trails) [113].”
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Sobhani, N., D’Angelo, A., Pittacolo, M., Roviello, G., Miccoli, A., Corona, S. P., Bernocchi, O., Generali, D., & Otto, T. (2019) · Cells · doi:10.3390/cells8040321 · Cited by 167
“In fact, alterations in the CCND1 gene or the p16Ink4a protein were neither in the phase II PALOMA-1 study [42], nor in the phase III PALOMA-2 trial [90] predictors of better survival for breast cancer patients.”
InfluentialEndocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies
Saatci, Ö., Huynh‐Dam, K., & Şahin, Ö. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02136-5 · Cited by 190
Recent advances of highly selective CDK4/6 inhibitors in breast cancer
Xu, H., Yu, S., Liu, Q., Yuan, X., Mani, S., Pestell, R. G., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0467-2 · Cited by 168
“received any treatment for this deadly disease [89].”
BackgroundDUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4
Jin, X., Yan, Y., Wang, D., Ding, D., Ma, T., Ye, Z., Jimenez, R., Wang, L., Wu, H., & Huang, H. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.036 · Cited by 166
“PD0332991 is a new-generation selective CDK4/6 inhibitor (Beaver et al., 2015; Finn et al., 2016; O’Leary et al., 2016).”
Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication
Klinge, C. M. (2018) · Non-Coding RNA · doi:10.3390/ncrna4040040 · Cited by 163
Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial
Trovo, M., Furlan, C., Polesel, J., Fiorica, F., Arcangeli, S., Giaj-Levra, N., Alongi, F., Del Conte, A., Militello, L., Muraro, E., et al. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.08.032 · Cited by 165
“half of whom had non-visceral disease [15].”
FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer
Wedam, S., Fashoyin-Aje, L., Bloomquist, E., Tang, S., Sridhara, R., Goldberg, K. B., Theoret, M. R., Amiri-Kordestani, L., Pazdur, R., & Beaver, J. A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2580 · Cited by 158
“On March 31, 2017, FDA granted regular approval for palbociclib as initial endocrine-based therapy for postmenopausal women in combination with any aromatase inhibitor based on PALOMA-2, amulticenter trial in whichmen were not eligible (13).”
BackgroundOvercoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Portman, N., Alexandrou, S., Carson, E., Wang, S., Lim, E., & Caldon, C. E. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-18-0317 · Cited by 163
An emerging generation of endocrine therapies in breast cancer: a clinical perspective
Patel, R. D., Klein, P., Tiersten, A., & Sparano, J. A. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00523-4 · Cited by 181
Regulation of breast cancer metastasis signaling by miRNAs
Petri, B. J., & Klinge, C. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09905-7 · Cited by 167
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
George, M. A., Qureshi, S., Omene, C. O., Toppmeyer, D., & Ganesan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.693104 · Cited by 165
“In ER+ breast cancer, they work synergistically with anti-estrogen therapies such as aromatase inhibitors, Fulvestrant and tamoxifen (1, 2, 4, 7, 17, 18).”
BackgroundTargeted therapy for breast cancer: An overview of drug classes and outcomes
Jacobs, A. T., Castaneda-Cruz, D. M., Rose, M. M., & Connelly, L. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115209 · Cited by 173
Tjan‐Heijnen, V. C. G., van Hellemond, I. E. G., Peer, P. G. M., Swinkels, A. C. P., Smorenburg, C. H., van der Sangen, M. J. C., Kroep, J. R., de Graaf, H., Honkoop, A. H., Erdkamp, F., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30600-9 · Cited by 172
Mills, J. N., Rutkovsky, A. C., & Giordano, A. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.04.009 · Cited by 152
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Joshi, J. J., Coffey, H., Corcoran, E., Tsai, J. J.-Y., Huang, C. L., Ichikawa, K., Prajapati, S., Hao, M., Bailey, S. L., Wu, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1865 · Cited by 162
“This observation led us to search for a combination partner to improve the response andwe tested the CDK4/6 inhibitor, palbociclib, as a potential partner due to its recent success in the breast cancer setting and on the rationale that the majority of growth factor pathways exert their effect through the cyclin D–CDK4…”
BackgroundWang, J., Li, B., Luo, M., Huang, J., Zhang, K., Zheng, S., Zhang, S., & Zhou, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01779-3 · Cited by 193
Rugo, H. S., Diéras, V., Gelmon, K. A., Finn, R. S., Slamon, D. J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D. R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy012 · Cited by 153
“All randomized patients received study therapy (supplementary Figure S1, available at Annals of Oncology online); additional methods are published elsewhere [4].”
MethodResultInfluentialSelf-citationLiang, J., Zbieg, J. R., Blake, R. A., Chang, J. H., Daly, S., DiPasquale, A. G., Friedman, L. S., Gelzleichter, T. R., Gill, M., Giltnane, J. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00847 · Cited by 155
Condorelli, R., Mosele, F., Verret, B., Bachelot, T., Bedard, P. L., Cortés, J., Hyman, D., Juric, D., Krop, I. E., Bièche, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz036 · Cited by 166
Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer
Gray, M., Meehan, J., Martínez-Pérez, C., Kay, C., Turnbull, A., Morrison, L. R., Pang, L. Y., & Argyle, D. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00617 · Cited by 189
“In post-menopausal women with ER/HER2 advanced breast cancer palbocicib can increase progression-free survival times when given in combination with letrozole compared with using letrozole alone (57).”
BackgroundThe role of epigenetic modifications in drug resistance and treatment of breast cancer
Fath, M. K., Azargoonjahromi, A., Kiani, A., Jalalifar, F., Osati, P., Oryani, M. A., Shakeri, F., Nasirzadeh, F., Khalesi, B., Nabi‐Afjadi, M., et al. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00344-6 · Cited by 166
The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Du, Q., Guo, X. Y., Wang, M., Li, Y., Sun, X., & Li, Q. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00880-8 · Cited by 167
Grinda, T., Antoine, A., Jacot, W., Blaye, C., Cottu, P. H., Dieras, V. C., Dalenc, F., Gonçalvès, A., Debled, M., Patsouris, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100114 · Cited by 154
Baelen, K. V., Geukens, T., Maetens, M., Tjan‐Heijnen, V. C. G., Lord, C. J., Linn, S., Bidard, F., Richard, F., Yang, W. W., Steele, R. E., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.006 · Cited by 159
Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1151 · Cited by 148
“Tumor response can be further enhanced with adjunctive therapy that includes mTOR inhibitors (3), isoform-specific PI3K inhibitors (4) and cyclin dependent kinase (CDK) 4/6 inhibitors (5-7).”
BackgroundResultEntinostat: a promising treatment option for patients with advanced breast cancer
Connolly, R. M., Rudek, M. A., & Piekarz, R. (2017) · Future Oncology · doi:10.2217/fon-2016-0526 · Cited by 148
Steinebach, C., Ng, Y. L. D., Sosič, I., Lee, C.-S., Chen, S., Lindner, S., Vu, L. P., Bricelj, A., Haschemi, R., Monschke, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc00167h · Cited by 148
Teh, J. L. F., & Aplin, A. E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1967 · Cited by 156
“While the use of CDK4/6 inhibitors in breast cancer is relatively advanced, it is becoming clear that clinical resistance frequently occurs in treated patients (17).”
BackgroundSelective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs
Yuan, K., Wang, X., Dong, H., Min, W., Hao, H., & Yang, P. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.05.001 · Cited by 156
O’Brien, N. A., McDermott, M. S. J., Conklin, D. F., Luo, T., Ayala, R., Salgar, S., Chau, K., DiTomaso, E., Babbar, N., Su, F., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01320-8 · Cited by 155
Self-citationThe History of Early Breast Cancer Treatment
Ben-Dror, J., Shalamov, M. M., & Sonnenblick, A. (2022) · Genes · doi:10.3390/genes13060960 · Cited by 167
“It showed significantly longer progression-free survival (PFS) when compared with only letrozole therapy [42].”
ResultWick, W., Dettmer, S., Berberich, A., Keßler, T., Karapanagiotou‐Schenkel, I., Wick, A., Winkler, F., Pfaff, E., Brors, B., Debus, J., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy161 · Cited by 157
Cornell, L., Wander, S. A., Visal, T. H., Wagle, N., & Shapiro, G. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.023 · Cited by 149
“…factor receptor 2-negative (HER2 − ) breast cancer based on prolonged progression-free survival when these agents are combined with hormone treatment compared to hormone therapy alone (Cristofanilli et al., 2016; Finn et al., 2016; Goetz et al., 2017; Hortobagyi et al., 2016; Sledge et al., 2017).”
Endocrine-Resistant Breast Cancer: Mechanisms and Treatment
Hartkopf, A. D., Grischke, E., & Brucker, S. Y. (2020) · Breast Care · doi:10.1159/000508675 · Cited by 149
Mayer, E. L., Ren, Y., Wagle, N., Mahtani, R. L., Ma, C. X., DeMichele, A. M., Cristofanilli, M., Meisel, J. L., Miller, K. D., Abdou, Y. G., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01940 · Cited by 151
Self-citationGuarducci, C., Bonechi, M., Benelli, M., Biagioni, C., Boccalini, G., Romagnoli, D., Verardo, R., Schiff, R., Osborne, C. K., Angelis, C. D., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0092-4 · Cited by 153
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
Santa-Maria, C. A., Kato, T., Park, J.-H., Kiyotani, K., RADEMAKER, A. W., Shah, A. N., Gross, L., Blanco, L. Z., Jain, S., Flaum, L., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24867 · Cited by 143
Pandey, K., Park, N., Park, K.-S., Hur, J., Cho, Y. B., Kang, M., An, H.-J., Kim, S., Hwang, S., & Moon, Y. W. (2020) · Cancers · doi:10.3390/cancers12123566 · Cited by 129
“In HR-positive/HER2-negative metastatic breast cancer, CDK4/6 inhibitors combined with an aromatase inhibitor are used as first-line therapy [7], and CDK4/6 inhibitors combined with fulvestrant are used as second-line therapy when the aromatase inhibitor treatment fails to prolong progression-free survival [8–10].”
BackgroundMethodOvercoming Endocrine Resistance in Hormone Receptor–Positive Breast Cancer
Al-Fakeeh, A., & Brezden‐Masley, C. (2018) · Current Oncology · doi:10.3747/co.25.3752 · Cited by 140
Park, Y. H., Kim, T., Kim, G. M., Kang, S. Y., Park, I. H., Kim, J. H., Lee, K. E., Ahn, H. K., Lee, M. H., Kim, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30565-0 · Cited by 134
Self-citationMartín, M., Zielinski, C. C., Ruíz‐Borrego, M., Carrasco, E., Turner, N. C., Ciruelos, E., Muñoz-Mateu, M., Bermejo, B., Vila, M. M., Anton, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.013 · Cited by 147
DeMichele, A. M., Cristofanilli, M., Brufsky, A., Liu, X., Mardekian, J., McRoy, L., Layman, R. M., Emir, B., Torres, M. A., Rugo, H. S., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01409-8 · Cited by 144
“Patients in the present (unadjusted) analysis were older than those enrolled in PALOMA-2, and a higher percentage of patients across both cohorts had bone-only disease at baseline compared with PALOMA-2.”
MethodInfluentialSelf-citationZhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131
“In addition, they found that combination treatment of NSCLC with cisplatin and crizotinib induced ICD in vivo (Liu et al., 2019).”
BackgroundInfluentialPhase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma
Taylor, J. W., Parikh, M., Phillips, J. J., James, C. D., Molinaro, A. M., Butowski, N. A., Clarke, J. L., Oberheim-Bush, N. A., Chang, S. M., Berger, M. S., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2977-3 · Cited by 129
Shah, M., Nunes, M. R., & Stearns, V. (2018) · PubMed · Cited by 128
Brosnan, E. M., & Anders, C. K. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.35 · Cited by 138
“Two CDK 4/6 inhibitors combined with endocrine therapy prolong PFS and are FDA approved in the first line setting: palbociclib (86,87) and ribociclib (88).”
BackgroundOverall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Linden, H. M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811714 · Cited by 126
Palafox, M., Monserrat, L., Bellet, M., Villacampa, G. J., González-Pérez, A., Oliveira, M., Brasó‐Maristany, F., Ibrahimi, N., Kannan, S., Mina, L. B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32828-6 · Cited by 154
“In closing, therapies for metastatic BC that progress on or after CDK4/6i treatment currently being tested in the clinic include: (1) ET or more potent SERDs in endocrine sensitive patients, albeit this patient population is difficult to identify (NCT02338349, NCT03616587); (2) continuation of CDK4/6i with a different…”
Rugo, H. S., Brufsky, A., Liu, X., Li, B. C., McRoy, L., Chen, C., Layman, R. M., Cristofanilli, M., Torres, M. A., Curigliano, G., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00479-x · Cited by 136
Self-citationDrugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
Alves, C. L., & Ditzel, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054522 · Cited by 141
García‐Recio, S., Hinoue, T., Wheeler, G. L., Kelly, B., Garrido-Castro, A. C., Pascual, T., de Cubas, A. A., Xia, Y., Felsheim, B., McClure, M. B., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00491-x · Cited by 193
Lloyd, M. R., Wander, S. A., Hamilton, E., Razavi, P., & Bardia, A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221113694 · Cited by 109
Manjunath, M., & Choudhary, B. (2021) · Oncology Letters · doi:10.3892/ol.2021.12773 · Cited by 129
Shah, A., Bloomquist, E. W., Tang, S. W., Fu, W., Bi, Y., Liu, Q., Yu, J., Zhao, P., Palmby, T. R., Goldberg, K. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2369 · Cited by 123
“The FDA granted accelerated approval to palbociclib, an inhibitor of cyclin-dependent kinase (CDK) 4 and 6, in this setting in 2014 (3) based on results of the PALOMA-1 study (4) and more recently regular approval in 2017 based on the confirmatory PALOMA-2 trial (5).”
BackgroundCejalvo, J. M., Pascual, T., Fernández-Martínez, A., Brasó‐Maristany, F., Gomis, R. R., Perou, C. M., Muñoz-Mateu, M., & Prat, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.015 · Cited by 123
“patients recruited in the PALOMA-2 phase III clinical trial that led to the approval of palbociclib in the first-line advanced or metastatic setting in combination with letrozole [25,30].”
BackgroundCharacterization of circulating breast cancer cells with tumorigenic and metastatic capacity
Koch, C., Kuske, A., Joosse, S. A., Yigit, G., Sflomos, G., Thaler, S., Smit, D. J., Werner, S., Borgmann, K., Gärtner, S., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911908 · Cited by 124
“Interestingly, treatment with the CDK4/6 inhibitor Palboci-clib showed a concentration-dependent inhibition of CTC-ITB-01 growth, suggesting that the patient may have benefitted from this new line of therapy recently approved for ER + patients (Turner et al , 2015; Finn et al , 2016).”
BackgroundAre all cyclin-dependent kinases 4/6 inhibitors created equal?
Marra, A., & Curigliano, G. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0121-y · Cited by 123
Mechanisms of endocrine therapy resistance in breast cancer
Rasha, F. A., Sharma, M., & Pruitt, K. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111322 · Cited by 145
O’Leary, B., Cutts, R. J., Huang, X., Hrebien, S., Liu, Y., André, F., Loibl, S., Loi, S., García-Murillas, I., Cristofanilli, M., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa087 · Cited by 131
“309 JNCI J Natl Cancer Inst (2021) 113(3): djaa087”
Onesti, C. E., & Jérusalem, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1852934 · Cited by 127
Presti, D., & Quaquarini, E. (2019) · Cancers · doi:10.3390/cancers11091242 · Cited by 129
“The subsequent double-blind, phase III, randomized study, the PALOMA-2 trial, enrolled 666 postmenopausal women with HR+/HER2−MBC who had not received prior treatment for advanced disease (Table 2) [63].”
BackgroundCiruelos, E., Villagrasa, P., Pascual, T., Oliveira, M., Pernas, S., Paré, L., Escrivá-de-Romaní, S., Manso, L., Adamo, B., de Dueñas, E. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0844 · Cited by 119
“Disease progression (22) 1 patient did not start palbociclib n = 18 Screening failures Reasons: Missing inclusion/exclusion (4) Inclusion criteria (10) Exclusion criteria (3) Unknown (1)”
BackgroundTargeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
Rej, R. K., Thomas, J. E., Acharyya, R. K., Rae, J. M., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00136 · Cited by 122
Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases
Priedigkeit, N., Watters, R. J., Lucas, P. C., Basudan, A., Bhargava, R., Horne, W. T., Kolls, J. K., Fang, Z., Rosenzweig, M. Q., Brufsky, A., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.95703 · Cited by 131
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
Browne, I. M., André, F., Chandarlapaty, S., Carey, L., & Turner, N. C. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00676-9 · Cited by 134
Clinical Review on the Management of Hormone Receptor–Positive Metastatic Breast Cancer
McAndrew, N. P., & Finn, R. S. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00384 · Cited by 121
Self-citationSmyth, L. M., Tamura, K., Oliveira, M., Ciruelos, E., Mayer, I. A., Sablin, M., Biganzoli, L., Ambrose, H. J., Ashton, J., Barnicle, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3953 · Cited by 121
“Other/missing 1 (5) 0 4 (14) 1 (5) 4 (10) 5 (8)”
Mollaei, M., Hassan, Z. M., Khorshidi, F., & Langroudi, L. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101056 · Cited by 129
Pharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicity
Wang, B., Varela‐Eirin, M., Brandenburg, S. M., Hernandez‐Segura, A., van Vliet, T., Jongbloed, E. M., Wilting, S. M., Ohtani, N., Jager, A., & Demaria, M. (2022) · The EMBO Journal · doi:10.15252/embj.2021108946 · Cited by 113
“…(LY2835219), and ribociclib (LEE011) are approved for the treatment of hormone-sensitive and HER2-negative advanced breast cancer patients, where they have been shown to improve progression-free survival in largely metastasized breast cancer patient cohorts (Finn et al , 2016; Goetz et al , 2017).”
Eggersmann, T. K., Degenhardt, T., Gluz, O., Wuerstlein, R., & Harbeck, N. (2019) · BioDrugs · doi:10.1007/s40259-019-00337-6 · Cited by 128
“As a continued approval for this indication was contingent upon validation of the observed clinical benefit in a confirmatory trial, the results of the subsequent PALOMA-2 trial were highly anticipated [6].”
BackgroundResultInfluentialSelf-citationGroenland, S. L., Martínez-Chávez, A., van Dongen, M. G. J., Beijnen, J. H., Schinkel, A. H., Huitema, A. D. R., & Steeghs, N. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00930-x · Cited by 123
O’Shaughnessy, J., Petráková, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D., Hart, L. L., Villanueva, C., Jakobsen, E. H., Beck, J. T., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4518-8 · Cited by 124
“Enhanced treatment benefits in patients with de novo advanced disease have previously been described with the CDK4/6 inhibitor palbociclib in combination with letrozole in the PALOMA-2 trial [20].”
BackgroundZhang, P., Zhang, Q., Tong, Z., Sun, T., Li, W., Ouyang, Q., Hu, X., Cheng, Y., Yan, M., Pan, Y., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00172-9 · Cited by 125
Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis
Ethier, J.-L., Desautels, D. N., Amir, E., & MacKay, H. J. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.002 · Cited by 111
Targeting FGFR pathway in breast cancer
Pérez-García, J. M., Muñoz‐Couselo, E., Soberino, J., Racca, F., & Cortés, J. (2017) · The Breast · doi:10.1016/j.breast.2017.10.014 · Cited by 112
Piezzo, M., Chiodini, P., Riemma, M., Cocco, S., Caputo, R., Cianniello, D., Gioia, G. D., Lauro, V. D., Rella, F. D., Fusco, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176400 · Cited by 119
Malorni, L., Curigliano, G., Minisini, A. M., Cinieri, S., Tondini, C. A., D’Hollander, K., Arpino, G., Bernardo, A., Martignetti, A., Criscitiello, C., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy214 · Cited by 110
Palbociclib in metastatic breast cancer: current evidence and real-life data
Serra, F., Lapidari, P., Quaquarini, E., Tagliaferri, B., Sottotetti, F., & Palumbo, R. (2019) · Drugs in Context · doi:10.7573/dic.212579 · Cited by 109
Metadata
- Authors
- Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., Gauthier, E., Lu, D. R., Randolph, S., Diéras, V., & Slamon, D. J.
- Affiliations
- Universidad Complutense de Madrid (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-17
- Volume
- 375
- Issue
- 20
- Pages
- 1925-1936
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2552099557
- Cited by
- 3,007
- References
- 12
- Citations by year
- 2026: 278 · 2025: 346 · 2024: 349 · 2023: 343 · 2022: 310 · 2021: 363 · 2020: 299 · 2019: 260 · 2018: 284 · 2017: 157 · 2016: 9
- FWCI
- 210.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Health Research Board (ICORG-2016-1)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- palbociclib, letrozole, advanced breast cancer, estrogen receptor-positive breast cancer, HER2-negative breast cancer, CDK4/6 inhibitors, progression-free survival, postmenopausal women, neutropenia, febrile neutropenia, overall survival, first-line therapy, drug safety and tolerability, patient-reported outcomes, pharmacokinetics, objective response rate
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Female, Humans, Middle Aged, Neutropenia, Nitriles, Piperazines, Pyridines, Receptors, Estrogen, Triazoles, Postmenopause, Disease-Free Survival, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.